Leuko is an MIT spinout developing PointCheckTM, the world's first medical device that can monitor white blood cells non-invasively. By enabling more frequent at-home monitoring, Leuko aims to improve clinical outcomes for more than >2M cancer chemotherapy patients a year in the US and Europe, reduce their chemotherapy-related hospital readmissions... Read more
Every year in the US, 850,000 cancer patients start chemotherapy, and 140,000 need to be hospitalized due to chemotherapy-induced febrile neutropenia (FN): a life-threatening infection which occurs while outpatients’ neutrophils (the most common white blood cell) are critically low. FN-related hospitalizations average 9 days, with an aggregated adm... Read more
